imatinib mesylate has been researched along with Hormone-Dependent Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dienes, HP; Engelmann, U; Gerharz, M; Heidenreich, A; Markert, E; Ohlmann, CH; Pfister, D | 1 |
| Blasick, TM; Brown, RE; Lun, M; Prichard, JW; Zhang, PL | 1 |
| Azevedo, I; Rocha, A; Soares, R | 1 |
| Chow, LW; Loo, WT; Toi, M; Yip, AY | 1 |
1 trial(s) available for imatinib mesylate and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzamides; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Drug Evaluation; Female; Humans; Imatinib Mesylate; Letrozole; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Pilot Projects; Piperazines; Postmenopause; Pyrimidines; Signal Transduction; Triazoles | 2008 |
3 other study(ies) available for imatinib mesylate and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
[Feasibility of targeted therapy based on immunohistochemical expression analysis in androgen-independent prostate cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bevacizumab; Biomarkers, Tumor; Biopsy; Cetuximab; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Imatinib Mesylate; Lymph Nodes; Male; Neoplasms, Hormone-Dependent; Piperazines; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Androgen; Taxoids; Trastuzumab | 2008 |
Morphoproteomic and pharmacoproteomic correlates in hormone-receptor-negative breast carcinoma cell lines.
Topics: Antineoplastic Agents; Benzamides; Breast Neoplasms; Captopril; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Hormones; Humans; Imatinib Mesylate; Immunohistochemistry; Interferon-alpha; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Piperazines; Proteomics; Pyrimidines; Receptors, Cell Surface | 2004 |
Progesterone sensitizes breast cancer MCF7 cells to imatinib inhibitory effects.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Benzamides; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Down-Regulation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Phosphorylation; Piperazines; Progesterone; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Tumor Stem Cell Assay | 2008 |